The Quality Lowdown: Valsartan Options, Supply Chain Warnings, Button Cameras
Executive Summary
Yet another valsartan approved as quality/shortage crisis unfolds, while warning letters hit firms on poor root cause investigations and supply chain issues, and FDA investigators procure shirt-button candid cameras.
You may also be interested in...
Jubilant Revenues Flat On LSI Decline
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in the LSI business and FDA action at two manufacturing units.
Jubilant Revenues Flat In Q2 On LSI Business Decline, FDA action
Jubilant reports higher second-quarter profits as it defers tax liability while revenues remain flat on the back of a decline in LSI business and FDA action at two manufacturing units.
FDA Warns Glenmark Over Temperature Excursions, Gritty Topicals
Firm should have addressed complaints of gritty topicals and compromised container/closures, and its own findings about overheated creams, the US FDA says.